Artivion, Inc. (NYSE:AORT) Shares Acquired by Tidal Investments LLC

Tidal Investments LLC boosted its position in Artivion, Inc. (NYSE:AORT - Free Report) by 14.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 179,806 shares of the company's stock after purchasing an additional 22,804 shares during the period. Tidal Investments LLC owned approximately 0.43% of Artivion worth $5,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of AORT. Wasatch Advisors LP raised its holdings in shares of Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after buying an additional 226,160 shares during the period. Point72 Asset Management L.P. bought a new position in Artivion in the 4th quarter valued at $5,573,000. First Trust Advisors LP purchased a new stake in Artivion in the fourth quarter worth $4,771,000. Next Century Growth Investors LLC lifted its position in shares of Artivion by 29.7% during the fourth quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock worth $14,085,000 after purchasing an additional 112,918 shares during the last quarter. Finally, Lord Abbett & CO. LLC lifted its position in shares of Artivion by 40.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 306,702 shares of the company's stock worth $8,769,000 after purchasing an additional 88,902 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Stock Up 0.6%

NYSE:AORT traded up $0.18 during mid-day trading on Monday, reaching $28.64. The company's stock had a trading volume of 241,597 shares, compared to its average volume of 326,494. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $32.33. The stock has a fifty day moving average of $25.13 and a 200-day moving average of $27.34. The firm has a market capitalization of $1.22 billion, a PE ratio of -1,432.00 and a beta of 1.54. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. Equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Activity at Artivion

In related news, insider John E. Davis sold 15,100 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the sale, the insider now owns 208,778 shares of the company's stock, valued at $4,929,248.58. This trade represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jean F. Holloway sold 18,020 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $425,452.20. Following the completion of the transaction, the senior vice president now owns 197,184 shares of the company's stock, valued at $4,655,514.24. This represents a 8.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,066 shares of company stock valued at $1,389,017 over the last ninety days. 7.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Needham & Company LLC restated a "buy" rating and issued a $32.00 price target on shares of Artivion in a report on Tuesday, May 6th. JMP Securities restated a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus lowered their price target on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.